Aeolus Pharmaceuticals Inc.' AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy

19 Apr 2007

·www.biospace.com

Radiation Therapy

LAGUNA NIGUEL, Calif.--(BUSINESS WIRE)--Aeolus Pharmaceuticals, Inc. (OTCBB:AOLS) announced the presentation of data by researchers at Loma Linda University Medical Center, National Jewish Medical and Research Center and Duke University showing that one of the Company’s metalloporphyrin antioxidants, AEOL 10113, demonstrated protection of healthy normal cells in mice with prostate tumor cells treated with radiation therapy. The study also showed that the compound did not interfere with the tumor destruction effects of the radiation therapy.

Organizations

National Jewish Health, Inc.

Duke University

Aeolus Pharmaceuticals, Inc.

[+2]

Indications

NeoplasmsProstatic Cancer

Targets

Drugs

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.